XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   36,083,301      
Beginning balance at Dec. 31, 2021 $ 199,059 $ 3 $ 414,348 $ (201) $ (215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under benefit plans (in shares)   63,552      
Issuance of common stock under benefit plans 51   51    
Stock-based compensation expense 3,531   3,531    
Vesting of restricted stock awards (in shares)   15,606      
Vesting of restricted stock awards 1   1    
Net unrealized gain (loss) on short-term investments (749)     (749)  
Net loss (28,100)       (28,100)
Ending balance (in shares) at Mar. 31, 2022   36,162,459      
Ending balance at Mar. 31, 2022 173,793 $ 3 417,931 (950) (243,191)
Beginning balance (in shares) at Dec. 31, 2021   36,083,301      
Beginning balance at Dec. 31, 2021 199,059 $ 3 414,348 (201) (215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain (loss) on short-term investments (2,253)        
Net loss (88,261)        
Ending balance (in shares) at Sep. 30, 2022   48,749,842      
Ending balance at Sep. 30, 2022 336,994 $ 5 642,795 (2,454) (303,352)
Beginning balance (in shares) at Mar. 31, 2022   36,162,459      
Beginning balance at Mar. 31, 2022 173,793 $ 3 417,931 (950) (243,191)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under benefit plans (in shares)   13,603      
Issuance of common stock under benefit plans 446   446    
Stock-based compensation expense 3,403   3,403    
Vesting of restricted stock awards (in shares)   6,235      
Vesting of restricted stock awards 1   1    
Net unrealized gain (loss) on short-term investments (309)     (309)  
Net loss (29,546)       (29,546)
Ending balance (in shares) at Jun. 30, 2022   36,182,297      
Ending balance at Jun. 30, 2022 147,788 $ 3 421,781 (1,259) (272,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued in a public offering, net of offering expenses (in shares)   12,432,432      
Common stock issued in a public offering, net of offering expenses 215,400 $ 2 215,398    
Issuance of common stock under benefit plans (in shares)   135,113      
Issuance of common stock under benefit plans 808   808    
Stock-based compensation expense 4,808   4,808    
Net unrealized gain (loss) on short-term investments (1,195)     (1,195)  
Net loss (30,615)       (30,615)
Ending balance (in shares) at Sep. 30, 2022   48,749,842      
Ending balance at Sep. 30, 2022 $ 336,994 $ 5 642,795 (2,454) (303,352)
Beginning balance (in shares) at Dec. 31, 2022 48,941,254 48,941,254      
Beginning balance at Dec. 31, 2022 $ 313,342 [1] $ 5 653,707 (1,958) (338,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued in a public offering, net of offering expenses (in shares)   9,583,334      
Common stock issued in a public offering, net of offering expenses 269,915 $ 1 269,914    
Issuance of common stock under benefit plans (in shares)   454,314      
Issuance of common stock under benefit plans 3,661   3,661    
Stock-based compensation expense 11,923   11,923    
Net unrealized gain (loss) on short-term investments 627     627  
Net loss (37,548)       (37,548)
Ending balance (in shares) at Mar. 31, 2023   58,978,902      
Ending balance at Mar. 31, 2023 $ 561,920 $ 6 939,205 (1,331) (375,960)
Beginning balance (in shares) at Dec. 31, 2022 48,941,254 48,941,254      
Beginning balance at Dec. 31, 2022 $ 313,342 [1] $ 5 653,707 (1,958) (338,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net unrealized gain (loss) on short-term investments 51        
Net loss $ (120,227)        
Ending balance (in shares) at Sep. 30, 2023 59,890,980 59,890,980      
Ending balance at Sep. 30, 2023 $ 503,048 $ 6 963,588 (1,907) (458,639)
Beginning balance (in shares) at Mar. 31, 2023   58,978,902      
Beginning balance at Mar. 31, 2023 561,920 $ 6 939,205 (1,331) (375,960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Public offering expenses (133)   (133)    
Issuance of common stock under benefit plans (in shares)   243,783      
Issuance of common stock under benefit plans 334   334    
Stock-based compensation expense 13,046   13,046    
Net unrealized gain (loss) on short-term investments (910)     (910)  
Net loss (41,192)       (41,192)
Ending balance (in shares) at Jun. 30, 2023   59,222,685      
Ending balance at Jun. 30, 2023 533,065 $ 6 952,452 (2,241) (417,152)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under benefit plans (in shares)   668,295      
Issuance of common stock under benefit plans 774   774    
Stock-based compensation expense 10,362   10,362    
Net unrealized gain (loss) on short-term investments 334     334  
Net loss $ (41,487)       (41,487)
Ending balance (in shares) at Sep. 30, 2023 59,890,980 59,890,980      
Ending balance at Sep. 30, 2023 $ 503,048 $ 6 $ 963,588 $ (1,907) $ (458,639)
[1] The condensed balance sheet as of December 31, 2022 has been derived from the audited financial statements as of that date.